Back

Platelet inhibitory profiles of prasugrel versus ticagrelor in patients with CYP2C19 loss-of-function genotypes undergoing percutaneous coronary intervention: results of a randomized feasibility study

1 September 2019 (12:40 - 13:30)
Organised by:
Congress Presentation Part of: Evolving developments in anti-platelet therapy Antiplatelet Drugs ESC Premium Access ESC Congress 2019

About the speaker

Photo
Professor Dominick Joseph Angiolillo

University of Florida College of Medicine – Jacksonville, Jacksonville (United States of America)

6 More presentations in this session

Presentation thumbnail
A randomized controlled trial evaluating outcome impact of cilostazol in patients with coronary artery disease and at a high risk of cardiovascular disease
Professor T. Chao (Taichung, TW)
Abstract
Presentation thumbnail
Pharmacodynamic effects of vorapaxar as an add-on antiplatelet therapy in patients with and without diabetes mellitus: the optimizing anti-platelet therapy in diabetes mellitus (OPTIMUS)-5 study
Professor D. Angiolillo (Jacksonville, US)
Abstract Slides
Presentation thumbnail
Effect of de-escalated switching dual antiplatelet therapy after acute myocardial infarction in patients undergoing percutaneous coronary intervention: real-world data from a nationwide cohort study
Doctor C. Hsu (Taipei, TW)
Abstract Slides
Presentation thumbnail
Predictors of DAPT use in patients beyond 1 year post myocardial infarction: Insights from the TIGRIS observational study
Doctor J. Russo (Ottawa, CA)
Abstract Slides
Presentation thumbnail
Comparing treatment recommendations for the DAPT and PRECISE-DAPT scores after percutaneous coronary intervention
Doctor R. Boudreau (Ottawa, CA)
Abstract Slides

Access the full session

Session thumbnail
Evolving developments in anti-platelet therapy

The Event

Event poster

ESC Congress 2019

1 September 2019 12:40 CET
You may be interested in
thumbnail
Webinar
Aspirin treatment for mitigating thrombotic risk across the cardiovascular risk continuum
thumbnail
Congress Presentation
Antithrombotic therapy in diabetes
thumbnail
Congress Session
State-of-the-art antithrombotic treatment in acute coronary syndromes: a paradigm shift?